Market Research Report
United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)
|United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)|
Published: December 17, 2018
Content info: 69 Pages
Delivery time: 1-2 business days
Overactive bladder (OAB) syndrome is a chronic medical condition which has a significant impact on the quality of life in a major amount of the population. Overactive bladder is the name given to a group of urinary symptoms that include a strong, uncontrollable urge to urinate at unexpected times, which may result in urine leakage (incontinence), and frequent urination during the day and night. OAB affects performance of daily activities and social functions such as work, traveling, physical exercise, sleep, and sexual function. OAB is a prevalent condition that affects the lives of millions of adults in the US and around the world. An estimated 30 million Americans suffer from overactive bladder, which is uncomfortable, disturbing, and potentially severe.
The treatment approaches for OAB includes behavioral therapy, such as bladder training and pelvic floor exercises. Second line treatment includes pharmacological intervention, historically with anticholinergic medications and more recently with the novel Beta 3 agonist mirabegron. For patients with persistent OAB symptoms, third-line treatment includes procedural therapy using BOTOX injected directly into the bladder to induce temporary muscle paralysis or neuromodulation to enhance neural signals and inhibit reflex detrusor contraction.
The US Overactive Bladder market is set to experience favorable growth driven by factors such rising ageing population, increasing health care expenditure, growing obese population, surging diabetic prevalence and increasing coffee intake. The major trends observed in this market include advancing innovative therapies, increasing awareness for OAB and development of gene therapy. However, the growth of the market is constrained by challenges such as entry of generic drugs in the market, stringent regulations and side effects of oral therapies of OAB.
The report "United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)" analyses the development of the respective market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth.